For mCRC, onartuzumab, a MET inhibitor, although phase II clinical trials have demonstrated its efficacy in combination with FOLFOX plus Bevacizumab, it is currently mainly used for non-small cell lung cancer (NSCLC) and has no further clinical trials related to gastrointestinal tumors [334]. This evidence concerns the gene MET and non-small cell lung carcinoma.